Apart from the fantastic scientific program, we have two very deserving candidates for the Pioneer and Distinguished Service Awards. Please take the opportunity to thank Larry Delver, recipient of the 2012 IETS Distinguished Service Award, for his dedication and important contributions to our society over the years. Larry is one of those individuals who has really made a change for our society by his outstanding participation in the Health and Safety Advisory Committee (HASAC), which has made our society internationally recognized as the international authority for the prevention of disease transmission. His efforts, along with those of the other members of this important committee of the IETS, helped in the recognition of the embryo as the safest means by which genetics can be moved around the world. Congratulations also go to Dr. O. J. Ginther, the recipient of the 2012 Pioneer Award. His pioneer work on utero-ovarian veno-arterial pathways in the control of luteal function; the use of ultrasonography to monitor follicular, luteal, and embryo/ fetal development in several domestic species; and the nonsurgical collection and transfer of bovine embryos, to name a few, have been major steps forward in the advancement of embryo transfer technologies as we know them today.
Members of the Local Organizing Committee, chaired by Chuck Long, have also worked on the social program. There will be ample opportunity to visit with friends and have a good time during the conference. Please look over the details of the scientific program. We believe that we have an outstanding scientific program for 2012, with format changes and Preconference Symposia designed to meet the interests and needs of all, regardless of their place in embryo transfer.
Finally, I would like to congratulate Pete Hansen on his election as the incoming vice president of the IETS. He will be working with Henrik Callesen, our 2012 IETS president, who will be taking over the leadership. I would also like to congratulate Matt Wheeler and Pascale Chavatte-Palmer for being re-elected to the IETS Board of Governors. We are very fortunate to have such an outstanding and dedicated group of people on the Board of Governors. They have given a lot of themselves on behalf of all of us to make the IETS what it is now. Being on the Board of Governors has been a fascinating experience, and I urge other members to submit your names next year as candidates for members of the Board of Governors or vice-president. IETS needs the involvement and compromise of our members to become an even stronger society. The venue will be a majestic landmark hotel in the heart of historic St. Augustine, Florida (the oldest city in the United States) and along the Atlantic Ocean. A social event to sample the pleasures of Florida's First Coast is planned.
IETS 2012 Committee Chairs
• The goal of the meeting is to identify approaches to advance the efficacy of transfer of embryos produced in vitro.
• The format is designed to maximize discussion; participants are encouraged to bring one or two slides of data to share.
Abstract. It has been 30 years since the first transgenic mouse was generated and 26 years since the first example of transferring the technology to livestock was published. While there was tremendous optimism in those initial years, with most convinced that genetically modified animals would play a significant role in agricultural production, that has not come to be. So at first sight one could conclude that this technology has, to a large extent, failed. On the contrary, it is believed that it has succeeded beyond our original expectations, and we are now at what is perhaps the most exciting time in the development and implementation of these technologies. The original goals, however, have drastically changed and it is now biomedical applications that are playing a central role in pushing both technical and scientific developments. The combination of advances in somatic cell nuclear transfer, the development of induced pluripotent stem cells and the completion of the sequencing of most livestock genomes ensures a bright and exciting future for this field, not only in livestock but also in companion animal species.
Additional keywords: animal models, bioreactors, somatic cell nuclear transfer, spinal cord repair, xenotransplantation.
Technical update
In this review we will cover technical advances that have played a major role in moving this technology forward, key areas where this technology is being applied and some challenges that are facing us. It would be impossible to cover all aspects of this technology in depth so we will focus on some salient points and will provide references to more comprehensive reviews covering specific areas. Initially, the goal of genetic modification in mammals was the introduction or addition of a new gene by techniques such as pronuclear injection, where a recombinant fragment of DNA (referred to henceforth as a transgene) is injected into the pronucleous of a recently fertilised zygote where it becomes stably integrated into random locations of the chromosome. This approach was mainly utilised for gain-of-function experiments to study the effects of overexpression of proteins of interest. While relatively efficient (3-25% of offspring born after pronuclear injection are transgenic) the technique has drawbacks including inability to target the transgene to specific locations of the chromosome, resulting in what is known as positional effect or position effect variegation (PEV; Opsahl et al. 2002) , and potential for random insertional mutagenesis. In addition, whereas it can be utilised for partial loss of function by use of silencing RNA methods (Xia et al. 2006; Choi et al. 2009; Yamaguchi et al. 2009; Pengyan et al. 2010) it cannot be used to completely silence a specific gene. In spite of these drawbacks, the production of transgenic livestock by pronuclear injection was successful in developing a range of transgenic animals for use in agriculture and medicine (reviewed by Niemann and Kues 2007) . Unfortunately, progress was slow and the number of laboratories involved in actively generating transgenic animals limited to a few. This was mostly due to the costs of production of transgenic animals; at one point these were calculated to be in the area of $50 000 per transgenic pig and $250 000 per transgenic cow (Wall et al. 1992) . These high costs prevented most laboratories, even when technically capable, from embracing this area of research.
In 1989, the laboratories of Mario Capecchi and Oliver Smithies established the technique of homologous recombination (HR; Folger et al. 1984; Smithies et al. 1984) . This approach allowed the introduction of very precise and targeted genetic modifications including the ability to disrupt genes (loss-of-function). This was quickly followed by increasingly complex modifications that could add, delete or exchange genes and very large chromosomal regions (reviewed by Laible and Alonso-González 2009). Unfortunately, unlike pronuclear CSIRO PUBLISHING Reproduction, Fertility and Development, 2011, 23, 56-63 www.publish. Brevini et al. 2008 Brevini et al. , 2010 . Whereas many groups have reported some sort of ES cell line, the reality is that to date we do not have any domestic animal ES cell lines that can be readily used for homologous recombination followed by chimera generation. So the field of transgenic livestock remained to a large extent static with few transgenic livestock being made by even fewer groups. Then in 1996 Keith Campbell and Ian Wilmut reported their results with somatic cell nuclear transfer (SCNT) and provided the platform for this new revolution in animal biotechnology (Campbell et al. 1996) . From the original observation in sheep, other groups quickly reported successful cloning in cattle (Cibelli et al. 1998 ), goats (Keefer et al. 2001 , pigs (Betthauser et al. 2000) , cats (Shin et al. 2002) , horses (Galli et al. 2003) and dogs (Lee et al. 2005) . Suddenly we had the required bridge between in vitro culture and live offspring. It was no surprise that the report of Dolly was quickly followed by reports of the first transgenic sheep (Schnieke et al. 1997 ) and the first genetargeted sheep (McCreath et al. 2000) both generated by SCNT. And while homologous recombination in non-ES cells such as fetal fibroblasts remains a daunting task, gene-targeted large animals have now been reported by several groups (reviewed by Laible and Alonso-González 2009).
So in term of technical developments, are we there yet? Not quite; as mentioned above homologous recombination remains a complex task. Fortunately, advances in this area are also continuing and systems such as the adeno-associated vectors (AAV) that were initially developed for applications in mice and humans have now been utilised successfully in domestic animals (Rogers et al. 2008a) . Moreover, there are other technologies, such as zinc-finger nucleases, which are being implemented with great success at the moment in species such as rats, and which are likely to work in cattle, pigs, dogs and cats (Durai et al. 2005; Rémy et al. 2010) . So while there is still the need to increase the efficiency and ease of gene targeting, and to ensure proper promoter regulation and increased efficiency of SCNT, the technology as it presently exists is not the limiting factor in the generation of transgenic livestock.
Genomic technologies: a levelling playing field
For many years one of the often cited criticisms of the use of large animals as biomedical models was the lack of genomic technologies for their analysis. These included lack of sequence availability and lack of comprehensive and high-quality genomic platforms such as microarrays and single nucleotide polymorphism (SNP) arrays. Fortunately, these differences have, to a large extent, disappeared. Complete genome sequences are available now for cattle, swine and horses. And with the availability of those sequences it is now possible to use new sequencing technologies such as ultra-high-throughput sequencing or 'deep sequencing' (Fox et al. 2009 ) to comprehensively examine gene expression profiling in livestock species. While still costly, the fact remains that these advances allow investigators to perform genetic analysis with the same detail in species whose genome has been sequenced. Now detailed analysis of gene expression profiles, single nucleotide polymorphism, chromatin modifications using immunoprecipitation techniques (ChiP) and even global methylation studies are possible and with the same depth of coverage in livestock as that obtained in humans and mice (Fox et al. 2009 ).
State of transition from technology to physiology
While technical advances continue to be developed, the reality is that we have the tools required to make genetic modifications in domestic animals as is evident by a quick examination of the literature, with an exponential increase in the number of publications describing transgenic livestock in recent years. And many of the same laboratories that were focussed on generating technology to produce transgenic large animals are now involved in the production and analysis of animals with complex phenotypes. In most cases, this requires a different skill and knowledge base necessitating the building of new collaborative groups that can tackle such complex problems. Thus, the field is at a critical crossroads where the technical advances are not the limiting factor any longer. The limiting factor is now the time and effort required to properly evaluate each of the transgenic lines that are being generated. In most cases a transgenic pig line can be generated in 6-9 months, yet its analysis may require 2-3 additional years of complex and costly research. Most laboratories are not equipped to handle and analyse multiple transgenic lines both due to costs and housing constraints. So the new bottleneck is composed of multiple factors including (1) lack of in-house expertise in the analysis of complex phenotypes, requiring the building of partnerships, (2) limited capabilities to house and maintain complex transgenic large animals, and (3) the costs associated with this type of research. The good news is that we can now focus on the reasons why we developed this technology instead on the technology itself. Table 1 shows a summary of publications related to the generation of transgenic livestock since 2008. It does not include publications where transgenic animals already generated where used for research but only those reporting the development of a new line. In some cases, similar lines were made by other groups before 2008. The idea of this table is not to be all-inclusive or to cover all generated lines to date, as this has been recently reviewed (Niemann and Kues 2007; Aigner et al. 2010) . What Table 1 represents is where these technologies are being applied at the moment. Initially, the main application of livestock transgenesis was the production of recombinant proteins in milk. Cattle, sheep, goats and even pigs continue to be developed for this purpose. In swine the focus was, and continues to be, in transplantation (reviewed by Klymiuk et al. 2010) with the majority of transgenic swine generated to date being for use in this area. In addition, there are many other applications beyond 
Representative applications of transgenic livestock
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transplantation. This include models of diabetes, cystic fibrosis, skin disorders and a wide range of transgenic lines that can be used to track the fate of cells (e.g. using green fluorescent protein (GFP) and red fluorescent protein (RFP) labelling). As shown in Table 1 , the most commonly used species for livestock transgenesis is swine due to the physiological similarities to humans and greater overall efficiency of production due to the relatively short gestational intervals and larger litter sizes. In cattle and goats the emphasis is on production of proteins in the mammary gland. By far the majority of the work is in the biomedical field, not in agriculture.
Lessons learned: livestock are not big mice
One of the main hurdles to the increased application of transgenic swine is the difficulty of obtaining research funding. While there are many reasons for this, a major factor is the 'monopoly' mice have in the area of transgenic animals models. This is due to their long history of use, their ease of genetic manipulation, widely available housing, availability of genomic and non-genomic tools and familiarity with the system by both reviewers and funding agencies. As a result, livestock applications are targeted to areas where they have a clear advantage over mice, or where the mouse model is known to be limiting. This is obvious in areas such as production of bioactive compounds in the mammary glands and in xenotransplantation, but when it comes to disease models the advantages are casespecific. That is, there must be a weakness in the transgenic mouse model that can be overcome by the use of large animal species. So what have we learned in terms of working with large animal models? One excellent example of the advantages of transgenic livestock beyond their size is the cystic fibrosis model. In humans, deficiencies in the cystic fibrosis transmembrane conductance regulator results in lung, pancreatic, liver and gallbladder pathologies that eventually results in death of the patient. The same genetic modification in mice, however, leads to intestinal defects but they fail to develop airway, pancreatic, liver or gallbladder disease. As a result, the mouse model is not useful for any translational studies such as the development of gene (Stoltz et al. 2010) . Therefore, it is not just a matter of size, but a matter of a physiological system that most closely resembles humans. A particularly striking case of the difference between mice and livestock, with respect to a response to a transgene, was recently reported by our laboratory (McCalla-Martin et al. 2010) . In an effort to develop a porcine model of basal cell carcinoma (BCC), the human activated Gli2 oncogene was expressed in keratinocytes of transgenic pigs by the use of a bovine K5 promoter. This identical construct had been utilised in mice by others to develop a model of basal cell carcinoma and basaloid follicular hamartomas with no psoriasis-like phenotype (Sheng et al. 2002) . Yet the exact same transgene produced severe ulcerative lesions in swine and these lesions resembled those seen in psoriasis. This was seen in multiple independent lines so it is not a line-specific issue. And while BCC-like lesions were also observed, the overall phenotype was very different from that seen in mice. Thus, the two species differ drastically in response to the same stimulus (McCalla-Martin et al. 2010) . This raises the question as to which of the two models, the mouse or the pig, more closely serves as a model of human disease.
More importantly, however, it places into question the validity of using a single animal, the mouse, to make inferences about the role a particular gene modification plays in human diseases, or to use information generated from only one species to make rather sweeping conclusions as to the relevance of an observation to human disease. While there is no question that mice have, and will continue to play, a major role in understanding disease, it is critical that additional animal models in species such as swine be generated to confirm and extend the findings made in mice.
Beyond transgenics: biomedical models for stem cell research
As SCNT revolutionised the generation of transgenic large animals, induced pluripotent stem cells (iPS) are likely to revolutionise the clinical application of stem cells (reviewed by Zhao and Daley 2008) . And while the mouse has been key in the development and testing of iPS technology, when it comes to clinical applications there is a dire need for large-animal models that can facilitate translational research. In this area there have been numerous transgenic lines generated that can be used to track cells including GFP and RFP (Table 1) . Furthermore, diabetic models being generated by several groups are likely to play a significant role in the development of stem cell-based therapies that can result in correction of the disease.
However, non-transgenic models are also likely to play a key role. In particular, the use of identical animals generated by SCNT that can be used to transplant cells and examine the behaviour of the transplanted cell in the absence of immune rejection. This model system has been tested by several laboratories (Klassen et al. 2008) . In our case, we have used SCNT to develop identical clones and used the system to create the first humane large-animal model of spinal cord injury (SCI). Spinal cord injury is a devastating condition with a high incidence in both humans and companion animals. At present, there is no effective therapy for severe spinal cord injury but there is a lot of interest in the potential of transplanted stem cells to produce both neuronal and glial lineages and thus to repair the spinal cord. These therapies have historically been tested in different rodent models, but the results of such studies do not always translate well to the clinical setting. There are multiple reasons for the failure in translation (Regenberg et al. 2009 ), but important considerations that may be addressed by a large mammalian model of spinal cord injury include the dramatic difference in body size between a mouse and a human, with implications for the distance of the injury site from the neuronal cell body and thus the axonal regenerative response. In addition, the size of the injury is much larger in a human than in a rodent, limiting the ability to evaluate techniques for delivery of appropriate cell volumes.
Developing a large mammalian model of spinal cord injury is associated with significant practical and ethical issues around the management of a large animal that is paralysed. However, animals have tails and they use their tails for a variety of functions including behavioural responses to changes in their environment (for example the wagging patterns of dogs' tails (Quaranta et al. 2007) ) and to provide balance to assist with locomotion (Walker et al. 1998) . Innervation of the tail derives from the caudal spinal cord segments that lie immediately after the sacral spinal cord segments. Models of sacrocaudal spinal cord injury in the rodent (Bennett et al. 1999 ) and cat (Ritz et al. 1992; Walker et al. 1998 ) have produced tail paralysis.
We hypothesised that transection of the porcine spinal cord at the junction between the sacral and caudal spinal cord segments would induce paralysis of the tail while sparing motor and autonomic (bladder and rectal) function. Using five SCNTcloned Yucatan Minipigs, we quantified the speed of tail wag, the normal tail position and the response to stimuli before inducing injury . We then transected the spinal cord just caudal to the last sacral spinal cord segment (identified by nerve stimulation intraoperatively). In three of the pigs, we transplanted GFP-labelled neural stem cells derived from 45-day-old fetuses of GFP-expressing Yucatan minipig SCNT clones directly into the transection site. Post-operatively, the pigs could stand and walk within an hour of surgery, but had complete paralysis of their tails, with loss of tail sensation (Fig. 1) . They maintained fecal and urinary continence. The animals were sacrificed and histopathological evaluation was performed at 1 and 4 weeks after injury and transplantation, and confirmed both complete spinal cord transection, and the survival and differentiation of transplanted GFP-labelled neural stem cells (Fig. 2) . Based on this initial proof-of-principle project, we conclude that we can safely induce a spinal cord injury that produces a quantifiable spastic paralysis of the pig tail, while sparing the ability to ambulate, urinate and defecate. Moreover, cells from identical clones can be transplanted into the injury site and will survive without being rejected. We can therefore use this model to investigate transplantation strategies that will promote axonal regeneration.
Transgenic large animal models
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This project illustrates how SCNT and stem cells can be combined to solve issues with significant clinical implications.
It also highlights what is often an overlooked application of these technologies, that is, that applications are not limited to human medicine but in many cases, such as in spinal cord repair, veterinary applications are also critically important not only for the benefit of the animal patient but also as clinical models that can help improve further application in both animals and humans.
Agricultural applications
It is ironic that the field that was the driving force in bringing this technology forward has, with time, been replaced by biomedical applications. This is due, in part, to the comparatively limited research resources available to work in this area, and to the public resistance to the consumption of products from genetically modified animals. In spite of both of these limitations, research in the area continues. In general, it has shifted from the initial goal of modification of growth properties, to the modification of milk properties and more recently to induction of disease resistance (reviewed by Wise et al. 2008) .
As consumption of products from genetically modified animals is perceived as a risk by the consumer, it is critical that a clear benefit from the genetic modification be demonstrated for this technology to have any chance of making inroads.
Unfortunately, there are few examples that demonstrate a clear consumer benefit. Increased growth rate or increased feed efficiency is not a benefit to the consumer unless accompanied by increased availability or reduced pricing.
Modifications that are more likely to be acceptable to the consumer and provide the needed impetus for the expansion of research efforts in the agricultural area are exemplified by the 'Enviro' pig developed by Golovan et al. (2001) . These pigs express phytase in the salivary gland resulting in reduced environmental impact due to a reduction of phosphorous in the manure. Similarly, pigs generated by overexpression of the humanised fat-1 gene resulting in increased levels of n-3 fatty acids (omega-3), and reduced ratios of n-6/n-3 fatty acids (Lai et al. 2006) can be perceived as having a health benefit. It is only through applications such as these, where the benefits are to society in general, that shifts in perception of the technology by the general public will take place. Until then, it is highly unlikely that publicly funded research efforts in agricultural transgenics will come even close to matching levels seen in biomedical research.
The future
The potential benefits of transgenic livestock have been discussed and reviewed by many for the last 20 years but for the most part the promise remained unfulfilled due to limited research efforts. It is only since the advance of SCNT that cost reductions and efficiency increases have made this technology available to a much larger group of investigators worldwide and this has resulted in an explosion of research in livestock October 27, 2011
Report to the President and the Board of Governors of the IETS Statistics and Data Retrieval Committee
A couple of changes were made this year, as I mentioned in last year's report.
1
We excluded the total number of ova collected by each practitioner. We think this has been a burden in the past because many practitioners do not record the UFOs and degenerate ova recovered. This leads to inaccurate figures that could be misconstrued, such as when comparing potential new superovulation protocols .
2 We also excluded the number of stored embryos from the 2011 report. Many practitioners do not keep accurate inventories of stored embryos and they have no idea how many their clients are storing in their own Dewars. Reporting in past years has been grossly underreported, so we decided to eliminate that data point.
Last year, the committee asked the Board of Governors for help with this report from the FASS office. However, there was not a good way to incorporate an outsider as a helper this year. I needed to complete my Excel template, which could only be done by me. Now that I have completed the template, maybe I can use some help next year. The training will be much easier now that all the formulas are in place. . All continents, with the exception of Africa, reported significant increases in the number of IVD embryos transferred. The number of frozen IVD embryos transferred into recipients outnumbered fresh transfers by 60,000 (328,000 frozen and 263,000 fresh). The trend toward more frozen than fresh transfers has held constant since the mid-1990s, when embryos began to be frozen using the direct transfer method.
Worldwide, 61,000 beef donors were flushed and 43,000 dairy cattle were flushed. These numbers are slightly inaccurate because the European bovine ET data were not separated into beef or dairy. 
Introduction
The goal of the Statistics and Data Retrieval Committee of the IETS is to collect complete in vivo and in vitro bovine, equine, swine, and small ruminant embryo collection and transfer statistics from every embryo transfer (ET) practitioner in every geographical area of the world. Collecting data is a great challenge each year for everyone involved, including the ET practitioners, who have to dig into their last year's files and assimilate the requested information.
Countries that are members of regional ET societies or associations, namely, the American Embryo Transfer Association, the European Embryo Transfer Association, the Canadian Embryo Transfer Association, and the Society of Brazilian Embryo Technology to name a few, are well organized and have established collection protocols that make reporting consistent from year to year. However, many countries do not belong to associations, and data collectors in those countries must call on the ET practitioners they know personally to provide them with data. This requires a tremendous amount of effort on behalf of the regional data collectors, and in many cases, not all practitioners are contacted. Certainly, much of the ET that is performed worldwide is not included in this report. However, efforts are ongoing to improve the system of collecting ET data to provide the industry with more complete and accurate numbers.
Currently, ET data are collected by country and organized by continent. See Table 1 Tables 7 to 12 of this document display the names of regional collectors and their respective countries so that new or existing ET teams in those areas know who to contact to submit data in the future.
Report of bovine in vivo-derived embryos in 2010
For the first time in 4 years, the reported number of flushes/ collections and the number of in vivo-derived (IVD) embryos transferred into recipients increased (Table 1A) . Although the number of bovine embryo collections was up by less than 1%, the number of embryos transferred was up by more than 10%. That is a substantial increase in 1 year. Frozen embryo transfers (+12.7%) made up most of that difference. With the exception of Africa, one notable trend is that growth appears to be equally distributed across all continents with respect to the number of embryos transferred. Oceania (R Pashen for Australia and J Forsyth for New Zealand) reported decreases in the number of flushes from 10,070 in 2009 to 8454 in 2010. However, the number of embryos transferred increased substantially from 2009 to 2010, from 46,095 to 59,765, respectively. As in last year's report, it is worth mentioning that these numbers are greatly underreported for both countries. Australia is not well organized between the veterinarians and nonveterinarians, which makes it extremely difficult to gather statistics from the latter group. Forsyth reported data from only one of seven known teams for 2010. It is unclear why the other six teams failed to report their ET numbers.
Globally, more frozen IVD embryos were transferred in 2010 than fresh embryos (327,525 and 263,036, respectively). That statistic held true for every continent except South America, where two times as many fresh embryos were transferred as frozen. The large number of available recipients throughout Brazil and Argentina is a likely reason for that.
The top five countries (Table 3) outside North America and Europe have not changed in the last year. 
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Report of bovine IVP embryos in 2010
Globally, the number of IVP embryos was up by 74,000 (25.9%) from a year ago. 
The overall activity of ET in other species in 2010
In this report, statistics are recorded for three species of small ruminants: sheep, goats, and deer. The reported number of viable sheep embryos flushed in 2010 was almost identical to the 2009 data (32,768 in 2009 and 32,614 in 2010 ; see Table 5 Only 84 cervid embryos were reported as being transferred in 2010 worldwide. R Mapletoft reported that one of his teams from Canada transferred 84 embryos in Mexico. The rest of the world had no deer ET activity to report.
The total number of equine flushes increased from 36,955 in 2009 to 41,652 in 2010, which is a 12.7% increase. Based on embryos transferred, the top three countries performing equine ET are Brazil, Argentina, and the United States, in that order. In 2010, Brazil equine ET practitioners transferred 14,422 embryos, which represented 43% of world's activity. Argentina reported 8226 embryos transferred. That equates to 29% of global activity. The United States was third again, with 18% of the equine workload. It is worth noting that 2 years ago worldwide, 24,000 mares were flushed. It appears that equine ET is back on track in 2010. Brazil increased its flush numbers by about 1100 in 2010, and Argentina increased its numbers by about 1800. The US equine ET data were actually estimated for the 2010 year because of an unfortunate fire that occurred at the Colorado State University (CSU) Equine Reproductive Center. P McCue, the director of that facility, is the US equine data retrieval representative for this committee. Unfortunately, he was too involved with organizing the aftereffects of the fire at the CSU breeding center to do an accurate survey for Unfortunately, no swine ET activity was reported from any continent or country in 2010. The United States reported 134 flushes in 2008, but only 9 flushes for 2009. It is unclear whether swine ET activity is actually down or the data are not being reported. This committee is in desperate need of regional data collectors of swine ET data.
Stored embryos
The committee has elected to discontinue reporting the number of embryos stored in liquid nitrogen. The reason is that the number actually being stored is vastly underreported. This committee's regional or country collectors only ask for the number of embryos stored by the ET practitioners. They do not ask for the number of embryos stored by the animal breeders. Because most embryos are stored in the Dewars of animal owners, and not those of the ET practitioners, it would be misleading to report only the number stored by practitioners. In addition, many practitioners do not have software that keeps an accurate count of stored embryo inventories. Therefore, this portion of the report will be omitted in the future. In previous annual reports, the number of imports has been included. However, the import-to-export ratio, which should be 1:1, is grossly uncorrelated. Very few practitioners ever report the number of embryos imported, so the committee will refrain from reporting imports unless the data are meaningful (i.e., a new country that has never reported any ET activity reports import data). In 2010, Sweden was such an example. The country imported and transferred 125 ovine embryos. A Canadian practitioner reported the work but failed to clarify the place of origin of the embryos.
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Exports and imports
Global maps of embryo transfer activity
For a quick visual reference, maps of continents or regions have been created to indicate those countries that reported ET activity in 2010. Yellow means that the country had a reAfrica remained stable in 2010, with the same five countries reporting for the last several years.
Asia improved its colors in 2010 by adding two new countries reporting in-country ET. Thailand and Korea have their own regional collectors, so they are now yellow along with Japan. In addition, China, Mongolia, and Russia had ET performed and reported by Canadian ET practitioners, so they are now light blue countries. We strongly encourage those countries to get their own regional or country data collector to begin reporting to the IETS annually. 
Countries and their regional data collectors in table format
Tables 7 to 12 are included in this report as a reference to continents and their regional and local data collectors. Anyone wishing to contribute ET statistics in these geographical areas can contact these collectors through the IETS at http:// www.iets.org.
A call to embryo transfer practitioners throughout the world
Although the goals of the committee are lofty, disseminating accurate data is not just for the benefit of this committee or the IETS, but for everyone in the ET industry, especially the practitioners. Every industry has its beginning, followed by a plateau of activity and eventually a decline and an end unless 
Conclusion
The volume of ET activity reported from all the committee's regional data collectors indicates that the ET industry is doing well worldwide. As always, the data from some countries are up and others are down, but fortunately, most are up from a year ago. Anyone reading this report should take into consideration that it does not include statistics from every country and that very few countries, if any, have 100% of their activity represented. To guess what percentage of the world's actual ET is represented in this document would be unprofessional at best, so no attempt is made to do so.
To make it easier for ET practitioners to collect data, the number of total ova collected is no longer requested by the committee. In addition, the number of stored embryos is no longer a part of the survey. This should eliminate a significant amount of time for each ET team to gather and report its statistics each year.
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Beltron EFT3002 Embryo Freezer
The EFT-3002 Embryo Freezer sets on top of your existing Semen tank and uses your LN2 to provide the cooling. Once the lower rod is frozen, there is no additional consumption of LN2 from your tank. The freezer can operate using 110v AC or 12v DC.
The freezing chamber will accommodate 64 straws in 32 drilled chambers. The freezing rate can be adjusted from 0. The program will include a keynote address by Dr. Stephen Ford titled "Maternal nutrition alters growth and development in both fetus and offspring." In addition, there will be a Practitioners' Forum on "Recent advances in the use of IVF and IVF frozen embryos in commercial embryo transfer."
In addition to the main program, there will be two preconference symposia on Saturday, (7 January 2012). The preconference symposia titles are "Recent advances in bovine reproduction and embryo transfer," organized jointly with IETS and AETA by Dr. Gabriel Bo and chaired by Dr. Reuben Mapletoft, and "The use of domestic animals as biomedical models," organized by Dr. Pascale Chavatte-Palmer, Dr. Matthew Wheeler, and the IETS DABE committee.
The Local Organizing Committee is planning a variety of social events. Tours will be available pre-and postmeeting. There will be an opening reception on Sunday evening, and Tuesday evening will include the closing banquet and activities.
Details about the program, including the invited speakers and titles of their presentations, are currently available on the IETS website: http://www.iets.org/2012.
All of these events will be held at the Renaissance Glendale Hotel and Spa. Registration and program information will be posted on the website as soon as it is available.
We once again urge all members to use the electronic submission format to help keep costs to a minimum.
We sincerely hope that you will all be able to join us in Phoenix to participate in this educational, fun, and exciting conference, IETS 2012! 
